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ABSTRACT
Objectives: To analyze the behavior of the prostate specific antigen velocity (PSAV) in lo-
calized prostate adenocarcinoma.
Materials and Methods: We conducted a retrospective study of 500 men who had localized
prostate adenocarcinoma, who underwent radical retropubic prostatectomy between January 1986
and December 1999. The PSAV was calculated for each patient and subsequently, the values were
correlated with 5 groups: age, initial PSA value, clinical stage, tumor volume and Gleason score.
Results: The behavior of PSAV presented statistic significance with an increment between
1.3 ng/mL and 9.6 ng/mL, ranging from 38.6% and 59.8% when compared with the initial PSA value
(p < 0.0001), clinical stage (p = 0.0002), tumor volume (p < 0.0001) and Gleason score (p = 0.0009).
Conclusion: PSAV up to 2.5 ng/mL/year is associated with factors of good prognosis, such
as initial PSA below 10 mg/mL, clinical stage T1, tumor volume below 20% and Gleason score lower
than 7.
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INTRODUCTION
Prostate cancer (PCA) is the most common
cancer in males from Europe, North America and
some African countries, occurring in 9.7% of all can-
cers in males, reaching 15.3% in developed coun-
tries and 4.3% in developing countries (1). Data from
the Brazilian National Cancer Institute (http://
w w w . i n c a . g o v . b r / e s t i m a t i v a s / 2 0 0 3 /
index.asp?link=tableestados.asp&UF=BR) estimate
that, in 2003, 35,200 new cases of PCA will be di-
agnosed and 8,200 men should die as a consequence
of it.
The most commonly used methods for de-
tecting PCA are the digital rectal examination, the
transrectal ultrasonography of the prostate and the
prostate-specific antigen (PSA). The digital rectal
examination has a sensibility between 40 and 80%,
specificity of 55% and a positive predictive value be-
tween 17 and 45% (2). Transrectal ultrasound (TRUS)
reaches detection rates between 2.3 and 14.6% with
positive predictive value between 17 and 36%, how-
ever, it presents low sensibility and specificity (3).
Currently, the PSA is the main diagnostic test for PCA,
being used for screening, prognosis, staging and cure
control (4), however, the PSA is not an ideal marker,
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because it has a false positive index of 10 to 40% and
positive predictive value of 46% (5). On the other
hand, up to 20% of patients with prostate cancer have
normal PSA (6).
Since the dosing of serum PSA is accompa-
nied by failure, variants of PSA measurements were
described in order to increase its accuracy: The free/
total PSA ratio (7), age-specific PSA (8), PSA den-
sity (9) and PSA velocity (PSAV) (10,11).
The objective of this work is to determine
the behavior of PSAV according to age, initial PSA
value, clinical stage, tumor volume and Gleason score,
in patients who underwent radical prostatectomy due
to localized prostate adenocarcinoma.
MATERIALS AND METHODS
We conducted a retrospective, non-con-
trolled, study based on the review of records from
patients who underwent radical prostatectomy be-
tween January 1986 and December 1999. The pa-
tients included in this study were assessed and
treated at São Paulo Hospital, from the Federal Uni-
versity of São Paulo, and Syrian Lebanese Hospi-
tal, São Paulo.
The study comprised 500 patients, with di-
agnosis of localized prostate cancer in stages T1c,
T2a, T2b, T2c and T3a, who underwent radical retro-
pubic prostatectomy (RRP) between 1986 and 1999,
with ages ranging from 42 to 76 years with a mean
age of 62.4 years.
For inclusion in the study, there was the re-
quirement of at least 2 PSA values previously to di-
agnosis with an interval not lower than 6 months be-
tween both samples.
Exclusion criteria were previous prostatic sur-
gery, prostatitis or urinary infection at the moment of
any PSA measurement (Hybritech Tandem-R e Abbott
Imx).
Surgical specimens (prostate, seminal
vesicles and lymph nodes) were evaluated by the same
pathologist (KML), analyzing the following patho-
logical parameters: histological grade, tumor volume,
surgical margins, infiltration of extra-prostatic tissue,
infiltration of seminal vesicles, lymph nodes me-
tastases and pathologic stage of disease.
In order to calculate the PSAV, the patients
were divided in 5 groups:
Group I = PSAV / Age – A) 40-49, B) 50-59,
C) 60-69, D) < 70;
Group II = PSAV / Initial PSA value – A) 0-4,
B) 4.1-10 C) 10.1-20 D) < 20
Group III = PSAV / Clinical stage - T1a-b-c,
T2a-b, T2c-T3;
Group IV = PSAV / Tumor volume (cc) – A)
0-20, B) 20-50, C) < 50;
Group V= PSAV / Gleason score – A) 2-3-4-
5-6, B) 7-8-9-10.
Evaluation Criteria
The PSAV was calculated for each patient by
the method of regression curve analysis in units/time
and percentage/time.
Statistical Analysis
Non parametric tests were used; for 2 vari-
ables, we used the Mann-Whitney test and for 3 or
more variables, we used the Kruskal-Wallis test. The p
value < 0.05 was considered statistically significant.
RESULTS
PSAV / Age in Years
No statistically significant differences were
found in PSAV between different age groups. The
majority of patients under study (81%) were in the
range of 50-70 years (Table-1).
PSAV / Initial PSA Value
We found statistically significant differences
in PSAV when PSA was < 10 ng/mL. The PSA veloc-
ity reached 2.3 ng/mL when PSA < 10 ng/mL, how-
ever, when PSA was higher than 10 ng/mL its veloc-
ity was higher than 5 ng/mL (Table-2).
PSAV / Clinical Stage
We found statistically significant difference
in PSAV when confronting clinical stage T1 with T2c-
T3a, according to PSA results in different stages of
disease, with the mean PSA in T1c tumors being equal
to 3.5 ng/mL, while in T2c-T3a tumors the mean
reached 6 ng/mL (Table-3).
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Table  1 – PSA Velocity (PSAV) in ng/mL relative to Patient Age in years.
Age Mean (PSAV) Median (PSAV)   n   %
40 – 49         4.6             3.3   20   4,0
50 – 59         4.4             2.8 127 25.4
60 – 69         4.2             2.7 278 55.6
70 – 79         5.3             3.0   75 15.0
H = 0.99; P = 0.8037
Table 2 – PSA Velocity (PSAV) in ng/mL relative to Initial PSA Value.
PSA Mean (PSAV)   Median (PSAV)                   n %
0 – 4   1.5 1.3   36   7.2
4.1 – 10   2.3 1.8 228 45.6
10.1 – 20   5.2 3.9 171 34.2
< 20 11.5 9.6   65 13.0
H = 176.29; P < 0.0001
PSAV / Tumor Volume
We found statistically significant difference
in PSAV when the tumor volume was < 20% of the
gland when compared to volumes between 21 – 50%
and > 50 (Table-4).
PSAV / Gleason Score
We found statistically significant differences
in PSAV between the 2 groups (Table-5).
Table 3 – PSA Velocity (PSAV) in ng/mL relative to Clinical Stage of prostate carcinoma.
Clinical Stage Mean (PSAV)                 Median (PSAV)                 n   %
T1 3.5 2.5 188 37.6
T2a-b 4.6 2.8 218 43.6
T2c-T3a 6.0 3.6   94 18.8
H = 16.68; P = 0.0002
Table 4 – PSA Velocity (PSAV) in ng/mL relative to Tumor Volume.
Tumor Volume (%) Mean (PSAV)   Median (PSAV)                        n %
0 – 20          3.5                         2.3                      305                      61.0
21 – 50          5.0                         3.5                      148                      29.6
< 50          9.3                         5.2                        40                        8.0
H = 35.74; P < 0.0001
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DISCUSSION
Our results show that the behavior of PSAV
compared to its initial value, clinical stage, tumor
volume and Gleason score, present a significant varia-
tion in PSAV with an increment between 1.3 ng/mL
and 9.6 ng/mL, ranging from 38.6% to 59.8%.
The difficulties for calculating the PSAV in-
clude its physiological variations between different
tests, and the fact that PSA is not prostate cancer spe-
cific, limits its use, however, it is believed that PSAV
has its maximal use for indicating biopsy for those
patients with normal PSA or repeating the biopsy in
cases of abnormal PSA (12).
Roehrborn et al. (13) studied the variability
of PSA in less than 90 days, in 295 patients having
BPH with PSA values below 10 ng/mL, and found
variations from 5.3 to 7.5 ng/mL between both PSA
measurements. Additionally they found 19% of pa-
tients with an increment higher than 0.75 ng/mL, con-
cluding that the PSA variability in a short time inter-
val is statistically significant.
An important study (14) compared the PSAV
in patients with BPH and PCA and verified that the
velocity was similar until 5 years before the diagno-
sis, however, between 7 and 9 years before the diag-
nosis the PSAV was higher in PCA. PSAV < 0.75 ng/
mL/year was detected 2.6 years before the diagnosis
in 72% of PCA cases, showing higher accuracy with
PSA < 4.0 ng/mL, increasing the specificity from 60%
to 90% (14). Our study revealed that all patients had
a PSAV higher than 1.3 ng/mL/year, almost twice the
value found by Carter et al. (14). Maybe the explana-
tion for such differences is due to the size of the
sample, since Carter et al. (14) worked with a group
of 11 patients with clinically localized carcinoma, and
our study group included 500 patients with clinically
localized carcinoma.
Smith & Catalona (10) determined a PSAV
above 0.75 ng/mL/year, as being the point of highest
sensibility (79%) and specificity (66%) for detecting
prostate cancer in those patients with initial PSA lower
than 4 ng/mL and under 70 years old. For initial PSA
higher than 4 ng/mL the cut-off point of highest sen-
sibility and specificity for detecting cancer was PSAV
of 0.4 ng/mL/year or more (10). Another study (15)
identified different values, finding a PSAV of 0.6 ng/
mL/year for patients with initial PSA lower than 4
ng/mL, and 1.0 ng/mL/year for patients with initial
PSA value higher than 4 ng/mL, in a group of 2,999
patients followed during 5 years for PCA screening.
Another study (16) with patients showing
PSA between 2.5 and 4 ng/mL, diagnosed BPH and
PCA by calculation of PSAV, being 0.38 ng/mL/year
and 0.52 ng/mL/year for BPH and PCA respectively,
additionally it showed a higher PSAV in younger pa-
tients. In contrast, our study revealed PSAV of 59%
and 1.3 ng/mL/year in the group of patients with PSA
lower than 4,0 ng/ml. Our results did not show statis-
tically significant differences concerning age.
Thiel et al. (17) analyzed the PSAV and its
role in the final pathologic prediction of PCA. They
detected a PSAV value of 1.1 ng/mL/year for localized
disease, and 1.9 ng/mL/year for non-confined disease.
We observed that there is variability in the
literature regarding the sensibility and specificity of
PSAV, with values from 55% to 79% and 66% to 96%
(11,13,18) respectively.
When the PSAV was higher than 0.75 ng/mL/
year the diagnosis of PCA was 47 to 70% (14), how-
ever, when the PSA is lower than 4 ng/mL, the pros-
tate biopsy is indicated when PSAV is lower than 20%
per year (19). In comparison to our results, all pa-
tients with PSAV higher than 1.3 ng/mL/year and
higher than 38.6% correlated to the diagnosis of pros-
tate cancer.
Table 5  –  PSA Velocity (PSAV) in ng/mL relative to Gleason Score.
Gleason               Mean (PSAV)                 Median (PSAV) n %
2-3-4-5-6                          3.9                             2.5                      312 62.4
7-8-9-10                          5.3                             3.3                      188 37.6
U = 24146.0; P < 0.0009
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Finally Schmid et al. (20) when studying 43
patients with untreated PCA, confirmed the doubling
time of PSA through sequential measurements, and
found that those patients with adverse factors showed
a doubling time significantly shorter than those with
favorable prognostic factors (24 versus 48 months in
average). Such data can be applied to our results; if
we analyze the PSAV values correlating them with
factors that are associated with a good prognosis, we
can observe that generally those patients with favor-
able elements such as low initial PSA, impalpable
tumors, low Gleason and smaller tumors, have PSAV
about 2.5 ng/mL/year.
One critic to the present study, would be the
difficulty of working with PSAV due to the test’s large
variability, caused mainly by physiological variations
and by the discrepancy between the different tests
employed.
Definitively it is impossible to reach a 100%
level of sensibility and specificity with PSA, even if
we create an ultra-sensitive PSA we will be able to
reach the ideal level. This is valid for PSAV as well.
Since this is the only available work on the
behavior of PSAV in patients with localized prostate
cancer including an expressive number of patients, it
is necessary to perform prospective and randomized
studies in order to confirm such findings.
CONCLUSION
A low PSAV (about 2.5 ng/mL/year) was as-
sociated with factors of good prognosis such as ini-
tial PSA lower than 10 ng/mL, clinical stage T1, tu-
mor volume lower than 20% and Gleason score lower
than 7, not changing with age.
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